Business Context and Reporting Period
Company: BioCardia, Inc. (BCDA)
Filing Type: Form 8-K (Current Report)
Date of Report: August 4, 2025
Reporting Period: Single event date (August 4, 2025)
This filing serves as a current report to disclose an update regarding the anticipated timing of regulatory activities for the company's primary product candidates.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This Form 8-K is a disclosure of a specific corporate event and does not contain financial statements or performance metrics.
Material Changes
Regulatory Update: On August 4, 2025, the company issued a press release (attached as Exhibit 99.1) updating the anticipated timing for regulatory approvals from the U.S. Food and Drug Administration (FDA) and the Japan Pharmaceuticals and Medical Devices Agency (PMDA).
Products Involved: CardiAMP® Cell Therapy System and Helix Transendocardial Delivery Catheter.
Guidance, Outlook, and Risks
Management Commentary: The filing references a press release containing the specific details of the regulatory timeline update. The text of the 8-K itself does not elaborate on the specific dates or the nature of the delay/acceleration beyond the existence of the update.
Risks and Contingencies: The filing does not explicitly list new risks or contingencies, though the subject matter implies ongoing regulatory uncertainty regarding the approval timeline for the CardiAMP system and Helix catheter.
Investor Verification Checklist
- Review the attached press release (Exhibit 99.1) for specific dates regarding FDA and PMDA approval timelines.
- Verify the current status of the CardiAMP® Cell Therapy System and Helix Transendocardial Delivery Catheter in clinical or regulatory review.
- Check subsequent filings for any financial impact resulting from the updated regulatory timeline.
- Confirm if the updated timeline affects the company's cash burn rate or capital requirements.